Health Catalyst (NASDAQ:HCAT) Given New $9.00 Price Target at Stephens

Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price target hoisted by equities researchers at Stephens from $7.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Stephens' price objective would indicate a potential upside of 6.51% from the stock's previous close.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. lifted their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 4th. Citigroup lifted their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday. Piper Sandler decreased their target price on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a research note on Monday, August 26th. Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research note on Thursday, November 7th. Finally, Evercore ISI boosted their target price on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $11.71.

Health Catalyst Trading Down 2.4 %

Shares of NASDAQ HCAT traded down $0.21 during midday trading on Thursday, hitting $8.45. The stock had a trading volume of 388,870 shares, compared to its average volume of 562,164. The company's 50-day simple moving average is $8.13 and its 200 day simple moving average is $7.20. The firm has a market cap of $514.17 million, a P/E ratio of -6.34 and a beta of 1.32. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the business posted ($0.22) earnings per share. The firm's quarterly revenue was up 3.5% on a year-over-year basis. Research analysts anticipate that Health Catalyst will post -0.35 EPS for the current year.

Insider Activity

In other news, COO Daniel Lesueur sold 8,137 shares of the business's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at $1,062,018.64. The trade was a 5.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares of the company's stock, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the transaction, the chief operating officer now directly owns 140,108 shares of the company's stock, valued at $1,062,018.64. This trade represents a 5.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock worth $257,555 over the last three months. Corporate insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Millrace Asset Group Inc. acquired a new position in Health Catalyst during the third quarter valued at approximately $1,568,000. Primecap Management Co. CA lifted its position in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company's stock valued at $19,572,000 after buying an additional 25,000 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $145,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Health Catalyst by 118.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 131,532 shares of the company's stock worth $1,071,000 after purchasing an additional 71,201 shares during the period. Finally, Quest Partners LLC bought a new position in shares of Health Catalyst during the third quarter worth approximately $34,000. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.